We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Bio-Rad Acquires GnuBIO and Fast Integrated DNA Sequencing Platform

By LabMedica International staff writers
Posted on 20 Apr 2014
Global life science and clinical diagnostics company Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA) has purchased GnuBIO, Inc. (Cambridge, MA. USA), a privately-held company that has developed a novel droplet-based DNA sequencing technology and a system that incorporates all DNA sequencing functions into a single, integrated workflow for medical diagnostics as well as research markets.

While other sequencing technologies require separate workflows for target selection, DNA amplification, DNA sequencing, and analysis, GnuBIO's technology integrates the entire workflow into a single, low-cost solution that produces results within hours, versus days.

GnuBIO's innovative system utilizes microfluidic and emulsion technology to perform complex, multiplexed reactions in droplets. The platform integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing, to informatics. This capability offers a “Sample In, Answer Out” solution for performing more complete workflows whereby a clinical lab technician or a researcher simply loads genomic DNA into the cartridge and presses a button to start the run, with results delivered within hours.

“Bio-Rad’s leading positions in the clinical IVD market as well as the Droplet Digital PCR space make Bio-Rad the ideal acquisition partner for us,” said John Boyce, president, CEO, and founder of GnuBIO. “Bio-Rad’s reputation as well as its presence in both the clinical and research markets will be essential elements to the success of the GnuBIO platform. We are very excited to join the Bio-Rad family,” Mr. Boyce added. With this acquisition, Bio-Rad will expand its Digital Biology Center and establish a research and development site in Cambridge (MA, USA).

"We are pleased to have GnuBIO join Bio-Rad," said Norman Schwartz, Bio-Rad President and CEO; "We believe GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage Bio-Rad's leadership role in the area of droplet digital PCR."

Related Links:

Bio-Rad Laboratories
GnuBIO 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.